The U.S. Food and Drug Administration (FDA) published a report entitled纳米技术 - 在进步与创新的十年that highlights FDA’s advancements in the field of nanotechnology since it released its last report in 2007. The report also reviews FDA’s role in advancing the public health through its regulation of products within its jurisdiction that involve the application of nanotechnology. According to the report, FDA “will rely on a combination of horizon-scanning activities to stay abreast of new developments and product applications, including by”:

  • Participating in scientific and trade forums;
  • Participating in standards development;
  • 继续与国内和国际同行讨论;
  • 监测科学和贸易文献;
  • Engaging with academia and developers; and
  • Performing prospective regulatory science on emerging technologies.

此外,FDA指出,其新兴科学工作组,一个跨机构,成立于2016年科学为基础的论坛,继续以确定相关的科学和技术发展趋势,以美国FDA的监管职责,包括对纳米技术产品。FDA指出,其“以科学为基础,以产品为中心的监管框架是足够灵活和强大,以帮助确保产品的安全性(和有效性,如适用),同时支持创新的有益纳米技术产品的开发。”

OnAugust 13, 2020, FDA will举办研讨会提出报告。研讨会将包括纳米技术的基础知识以及将突出设施,管理科学的研究,指导性文件,标准,国内和国际的合作,并在监管科学的新挑战。演讲者是阿尼尔K.帕特里,博士,主席,纳米技术工作组,主任,纳米核,国家毒理学研究中心(NCTR)/ FDA。